Camus Marine, Jensen Dennis M, Ohning Gordon V, Kovacs Thomas O, Jutabha Rome, Ghassemi Kevin A, Machicado Gustavo A, Dulai Gareth S, Jensen Mary E, Gornbein Jeffrey A
*CURE Hemostasis Research Group, CURE Digestive Diseases Research Center, David Geffen School of Medicine at UCLA †Division of Digestive Diseases at UCLA Ronald Reagan Medical Center §Gastroenterology Division at VA Greater Los Angeles Healthcare Center ∥Department of Biomathematics, University of California, Los Angeles, CA ‡Department of Gastroenterology, Lariboisiere Hospital, APHP, University Paris 7, Paris, France.
J Clin Gastroenterol. 2016 Jan;50(1):52-8. doi: 10.1097/MCG.0000000000000286.
Improved medical decisions by using a score at the initial patient triage level may lead to improvements in patient management, outcomes, and resource utilization. There is no validated score for management of lower gastrointestinal bleeding (LGIB) unlike for upper gastrointestinal bleeding. The aim of our study was to compare the accuracies of 3 different prognostic scores [Center for Ulcer Research and Education Hemostasis prognosis score, Charlson index, and American Society of Anesthesiologists (ASA) score] for the prediction of 30-day rebleeding, surgery, and death in severe LGIB.
Data on consecutive patients hospitalized with severe gastrointestinal bleeding from January 2006 to October 2011 in our 2 tertiary academic referral centers were prospectively collected. Sensitivities, specificities, accuracies, and area under the receiver operator characteristic curve were computed for 3 scores for predictions of rebleeding, surgery, and mortality at 30 days.
Two hundred thirty-five consecutive patients with LGIB were included between 2006 and 2011. Twenty-three percent of patients rebled, 6% had surgery, and 7.7% of patients died. The accuracies of each score never reached 70% for predicting rebleeding or surgery in either. The ASA score had a highest accuracy for predicting mortality within 30 days (83.5%), whereas the Center for Ulcer Research and Education Hemostasis prognosis score and the Charlson index both had accuracies <75% for the prediction of death within 30 days.
ASA score could be useful to predict death within 30 days. However, a new score is still warranted to predict all 30 days outcomes (rebleeding, surgery, and death) in LGIB.
在患者初始分诊阶段使用评分来改善医疗决策,可能会提升患者管理水平、改善治疗结果并提高资源利用率。与上消化道出血不同,目前尚无经过验证的用于下消化道出血(LGIB)管理的评分。我们研究的目的是比较3种不同预后评分[溃疡研究与教育中心止血预后评分、查尔森指数和美国麻醉医师协会(ASA)评分]对严重LGIB患者30天再出血、手术和死亡的预测准确性。
前瞻性收集了2006年1月至2011年10月期间在我们2家三级学术转诊中心因严重胃肠道出血住院的连续患者的数据。计算了这3种评分对30天再出血、手术和死亡率预测的敏感性、特异性、准确性以及受试者工作特征曲线下面积。
2006年至2011年期间纳入了235例连续的LGIB患者。23%的患者发生再出血,6%的患者接受了手术,7.7%的患者死亡。在预测再出血或手术方面,每种评分的准确性均未达到70%。ASA评分对预测30天内死亡率的准确性最高(83.5%),而溃疡研究与教育中心止血预后评分和查尔森指数对预测30天内死亡的准确性均<75%。
ASA评分可用于预测30天内的死亡。然而,仍需要一种新的评分来预测LGIB患者30天的所有结局(再出血、手术和死亡)。